Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) on Tuesday, soared 0.24% from the previous trading day, before settling in for the closing price of $445.43. Within the past 52 weeks, VRTX’s price has moved between $377.85 and $519.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 21.61%. The company achieved an average annual earnings per share of 4183.21%. With a float of $256.00 million, this company’s outstanding shares have now reached $256.97 million.
Let’s determine the extent of company efficiency that accounts for 6100 employees. In terms of profitability, gross margin is 86.03%, operating margin of -6.69%, and the pretax margin is -2.7%.
Vertex Pharmaceuticals, Inc (VRTX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vertex Pharmaceuticals, Inc is 0.31%, while institutional ownership is 94.78%. The most recent insider transaction that took place on May 21 ’25, was worth 76,021. Before that another transaction happened on May 21 ’25, when Company’s Director proposed sale 170 for $447.18, making the entire transaction worth $76,021.
Vertex Pharmaceuticals, Inc (VRTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 4183.21% per share during the next fiscal year.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Trading Performance Indicators
Vertex Pharmaceuticals, Inc (VRTX) is currently performing well based on its current performance indicators. A quick ratio of 2.29 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.92, a number that is poised to hit 4.30 in the next quarter and is forecasted to reach 20.81 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc (VRTX)
Looking closely at Vertex Pharmaceuticals, Inc (NASDAQ: VRTX), its last 5-days average volume was 1.51 million, which is a drop from its year-to-date volume of 1.65 million. As of the previous 9 days, the stock’s Stochastic %D was 71.14%. Additionally, its Average True Range was 11.94.
During the past 100 days, Vertex Pharmaceuticals, Inc’s (VRTX) raw stochastic average was set at 40.21%, which indicates a significant decrease from 85.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.47% in the past 14 days, which was lower than the 30.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $470.30, while its 200-day Moving Average is $466.94. However, in the short run, Vertex Pharmaceuticals, Inc’s stock first resistance to watch stands at $451.04. Second resistance stands at $455.59. The third major resistance level sits at $461.34. If the price goes on to break the first support level at $440.73, it is likely to go to the next support level at $434.99. Should the price break the second support level, the third support level stands at $430.43.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Key Stats
Market capitalization of the company is 114.65 billion based on 256,797K outstanding shares. Right now, sales total 11,020 M and income totals -535,600 K. The company made 2,770 M in profit during its latest quarter, and 646,300 K in sales during its previous quarter.
